Gilead Sciences, Inc. (GILD)
After hours:
| Previous close | 81.39 |
| Open | 84.65 |
| Bid | 84.01 x 900 |
| Ask | 84.46 x 1800 |
| Day's range | 83.62 - 86.97 |
| 52-week range | 57.17 - 89.74 |
| Volume | |
| Avg. volume | 7,390,108 |
| Market cap | 105.983B |
| Beta (5Y monthly) | 0.43 |
| PE ratio (TTM) | 32.01 |
| EPS (TTM) | 2.64 |
| Earnings date | 26 Apr 2023 - 01 May 2023 |
| Forward dividend & yield | 2.92 (3.48%) |
| Ex-dividend date | 14 Dec 2022 |
| 1y target est | 87.54 |
- Zacks
Gilead (GILD) Q4 Earnings & Sales Top on Biktarvy & Oncology
Gilead's (GILD) Q4 earnings and sales beat on strong HIV and oncology business. The guidance for 2023 was also ahead of expectations.
- Business Wire
U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer
FOSTER CITY, Calif., February 03, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) has approved Trodelvy® (sacituzumab govitecan-hziy) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in
- Motley Fool
Is Gilead Sciences Stock a Screaming Buy After Its Strongest Results in 7 Years?
Despite a slower start this year, Gilead appears to be in pretty good shape to resume its momentum. CEO Dan O'Day stated in the press release announcing the numbers, "2022 marked Gilead's strongest full-year growth in our base business since HCV sales peaked in 2015." Is Gilead Sciences stock a buy after its strongest results in seven years?
